Literature DB >> 4978883

Rare earth nuclides as potential agents for skeletal imaging.

R E O'Mara, J G McAfee, G Subramanian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4978883

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  6 in total

Review 1.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

2.  Studies on incorporated short-lived beta-emitters with regard to the induction of late effects.

Authors:  W A Müller; E H Scháffer; U Linzner
Journal:  Radiat Environ Biophys       Date:  1980       Impact factor: 1.925

3.  A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical.

Authors:  Jaime Simón; R Keith Frank; Druce K Crump; William D Erwin; Naoto T Ueno; Richard E Wendt
Journal:  Nucl Med Biol       Date:  2012-03-28       Impact factor: 2.408

4.  Samarium-153 chelate localization in malignant melanoma.

Authors:  J H Turner; A A Martindale; G C de Witt; J Webb; P Sorby; R E Boyd
Journal:  Eur J Nucl Med       Date:  1987

Review 5.  Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Authors:  B L R Kam; J J M Teunissen; E P Krenning; W W de Herder; S Khan; E I van Vliet; D J Kwekkeboom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

6.  (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

Authors:  Ralf Bergmann; Marian Meckel; Vojtěch Kubíček; Jens Pietzsch; Jörg Steinbach; Petr Hermann; Frank Rösch
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.